Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hetastarch
Drug ID BADD_D01066
Description Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
Indications and Usage An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.
Marketing Status Not Available
ATC Code B05AA07
DrugBank ID DB09106
KEGG ID D03335
MeSH ID D006895
PubChem ID 24846132
TTD Drug ID Not Available
NDC Product Code 0409-7248; 18124-009; 0409-1555
Synonyms Hydroxyethyl Starch Derivatives | Derivatives, Hydroxyethyl Starch | Starch Derivatives, Hydroxyethyl | Hydroxyethylated Starches | Starches, Hydroxyethylated | Starches, 2-Hydroxyethyl | 2-Hydroxyethyl Starches | Starches, 2 Hydroxyethyl | Hemohes | Elohes | Hespan | Hetastarch | Pentafraction | Pentaspan | Pentastarch | Plasmasteril | HAES-steril | Hydroxyethyl Starch 130-0.4 | Hydroxyethyl Starch 130 0.4 | Hydroxyethyl Starch (130 KD-0.4 Substitution)
Chemical Information
Molecular Formula C29H52O21
CAS Registry Number 9004-62-0
SMILES CC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)OC)O)O)OC4C(C(C(C(O4)CO)OC)O)OC CO)O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metabolic acidosis14.01.01.003--Not Available
Myalgia15.05.02.001--
Non-cardiogenic pulmonary oedema24.03.08.004; 22.01.03.006--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Pancreatitis07.18.01.001--
Parotid gland enlargement07.06.03.001--Not Available
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Pruritus23.03.12.001--
Pulmonary oedema02.05.02.003; 22.01.03.003--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Sepsis11.01.11.003--
Skin disorder23.03.03.007--Not Available
Sneezing22.02.05.011--
Stridor22.04.02.003--
Submaxillary gland enlargement07.06.03.003--Not Available
Tachycardia02.03.02.007--Not Available
Tachypnoea22.02.01.014--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular fibrillation02.03.04.008--
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Haemorrhage24.07.01.002--Not Available
Blood disorder01.05.01.004--Not Available
Apparent life threatening event22.11.02.001; 18.04.15.001; 17.02.05.043--Not Available
Transfusion-related circulatory overload12.02.08.006; 02.05.04.016--Not Available
Acquired Von Willebrand's disease01.01.01.004--Not Available
The 2th Page    First    Pre   2    Total 2 Pages